Breast Cancer
From the Journals
Cancer Cases, Deaths in Men Predicted to Surge by 2050
Researchers analyzed data from the 2022 Global Cancer Observatory (GLOBOCAN), which provides national-level estimates for cancer cases and deaths...
Commentary
Cancer Treatment 101: A Primer for Non-Oncologists
Doctor explains why he thinks time of diagnosis is the best time for molecular testing of a new malignant tumor.
Feature
Should All Patients With Early BC Receive Adjuvant Radiotherapy?
Researchers analyze data from a trial of 589 patients with early breast cancer, who were randomized to receive either high-dose or no radiotherapy...
From the Journals
Few Severe Toxicities After SBRT in Oligometastatic Cancer
SBRT, an alternative to chemotherapy and immunotherapy, offers treatment with a low rate (0.5%) of severe acute toxicities.
Feature
BRCA Mutations in Men: Important but Often Overlooked
Most are unaware of the associated cancer risks, and management recommendations for male BRCA carriers.
From the Journals
Modest Gains Shown in Breast Cancer Immunotherapy Trials
Researchers evaluated 331 immunotherapy trials, enrolling nearly 50,000 patients with breast cancer.
From the Journals
Can Addressing Depression Reduce Chemo Toxicity in Older Adults?
Researchers evaluated whether greater reductions in grade 3 chemotherapy-related toxicities occurred with geriatric assessment-driven...
From the Journals
The Last 30 Days: How Oncologists’ Choices Affect End-of-Life Cancer Care
Researchers analyze data from more than 17,000 patients who died of cancer between 2012 and 2017.
From the Journals
Ancient Viruses in Our DNA Hold Clues to Cancer Treatment
Targeting remnants of a virus in our DNA could lead to more effective cancer treatment with fewer side effects.
Conference Coverage
Outcomes with CDK4/6 Inhibitors Vary in BC
A large Italian study found real-world differences in short-term outcomes among first line CDK4/6 inhibitors palbociclib, ribociclib and...
Latest News
Black Women With Breast Cancer Face Clinical Inequities
Retrospective analysis finds no clinical trial enrollment, reduced use of targeted treatment, and shortened survival.